March 25th 2025
Under the agreement, AstraZeneca will use Alteogen’s proprietary hyaluronidase platform technology to develop and commercialize subcutaneous formulations of multiple oncology assets in its portfolio.
March 18th 2025
The partnership aims to develop and commercialize a novel checkpoint inhibitor for immuno-oncology applications.
January 24th 2025
The collaboration will combine fully automated and digitalized technologies to reduce CGT manufacturing timelines to 2.5 days.
January 22nd 2025
Cytiva will combine its CGT manufacturing technologies with Cellular Origins' robotic manufacturing platform.
January 17th 2025
Production is set to take place at Samsung Biologics’ Songdo, South Korea, site, and the agreement will run through December 2030, subject to change.